Xtal AI: Revolutionizing Drug Discovery with AI and Robotics – Smart Lab Solutions from XtalPi

XtalPi is a world-leading technology company driven by artificial intelligence (AI) and robotics innovation. Founded in 2015 at the Massachusetts Institute of Technology (MIT) in the United States, it is committed to achieving digital and intelligent transformation in the fields of life sciences and new materials. The company leverages cutting-edge technologies and capabilities such as quantum physics, artificial intelligence, cloud computing, and large-scale experimental robotics clusters to provide innovative technologies, services, and products for global industries including biomedicine, chemicals, new energy, and new materials.

XtalPi collaborates with numerous global multinational pharmaceutical companies, well-known pharmaceutical enterprises in China, and pioneering Biotech firms, such as Pfizer, Eli Lilly, CTTQ, and CK Life Sciences. Sixteen of the top 20 global multinational pharmaceutical companies have established stable partnerships with XtalPi. During the development of PAXLOVID, the world’s first FDA-approved oral small-molecule drug for COVID-19, XtalPi's team worked closely with Pfizer scientists to identify the optimal drug crystal form within just six weeks, significantly shortening the R&D cycle and accelerating the drug’s market launch. In 2023, XtalPi entered a collaboration with Eli Lilly to co-develop a first-in-class drug, with upfront payments and milestone-based earnings totaling $250 million, setting a new record for the highest single pipeline amount in China's AI-driven drug discovery sector.

At the 2023 World Artificial Intelligence Conference, XtalPi was awarded the highest honor of the conference, the SAIL Award, and named the "Treasure of the Hall," sharing the distinction with companies such as COMAC, Huawei, and Qualcomm. It was also the "only double winner" at the conference. XtalPi has also received honors and awards including the Hurun Global Unicorn List, Forbes China's Top 50 Most Innovative Companies, Fortune China’s Most Socially Impactful Startups, and MIT Technology Review’s annual "50 Smartest Companies."

ID4Inno™: Small Molecule Drug Discovery Platform

XtalPi's self-developed ID4Inno™ Artificial Intelligence Drug Discovery System is a proprietary platform that combines the efficiency of AI with physical accuracy. By leveraging AI and computational chemistry to empower drug discovery, it accurately and efficiently explores a broader chemical space. It achieves drug discovery milestones by synthesizing fewer but more novel molecules. The system includes two sub-platforms: ID4Idea™, an AI-based molecular generation and property prediction platform, and ID4Gibbs™, a high-precision, high-throughput computational chemistry platform.

Ailux Biologics: A Dedicated Brand for Biopharmaceutical Discovery

Ailux Biologics is a proprietary brand under XtalPi, dedicated to AI-powered discovery and engineering of biologics. Ailux operates at the intersection of life sciences and artificial intelligence, collaborating with leading global pharmaceutical companies and biotechnology firms to advance the development of the biopharmaceutical industry.

ChemArt™: Human-Machine Integrated Chemical Synthesis Services

XtalPi's Chemical Synthesis Service ChemArt™ relies on automated synthesis workstations, adopting a "human-machine integration" service model to enhance the efficiency of chemical synthesis services, providing professional and efficient chemical synthesis services for global biopharmaceutical enterprises.

Xtalgazer™: “Experiment+Calculation”Drug Solid Form R&D Services

Xtalgazer is XtalPiOne-Stop Service Platform for Crystal Research, which is based on high-precision computational simulation and artificial intelligence methods. Combined with the rich experience of industry experts and a highly automated crystallization experiment platform, it provides advanced, high-quality, and efficient drug solid form research and development services through the organic combination of physical models and AI models, as well as computation and experimentation.

XtalPi Xtalgazer Intelligent Crystallization Platform, by deeply integrating automation and intelligent technologies, aims to overcome the long-standing limitations of reliance on manual experience trial-and-error in solid-state R&D, transforming "blind screening" in traditional R&D models into more scientific and precise "rational design." This achieves rapid, comprehensive, and highly customized R&D processes, propelling the entire industry to new heights.

XtalDynamics™：AI+AutomationInitiate a New Paradigm in Scientific Research to Continuously Empower New Infrastructure

XtalPi has been exploring the independent research and development path of laboratory intelligence and automation since 2019, and has successfully applied automation to industries such as pharmaceuticals, chemical engineering, new materials, and new energy.

We ProvideAutomation products and services cover: one-stop construction services for smart laboratories, automated experimental islands with multiple automated workstations connected in series, and robotic workstations for specific automated application scenarios, includingXmartChem^®Intelligent Synthesis Workstation,XtalComplete^®Intelligent Crystallization Workstation,ChemPlus^®Desktop Solid Dispenser.We can provide personalized and scalable intelligent automation solutions based on customers' specific application needs, to help them address various challenges in an ever-changing work environment.

Scan the QR code to follow XtalPi's official website

Click to scan and register 

Swipe up and down to view the agenda

PRHub of Yaorong Circle aims to help biopharmaceutical technology enterprises with brand promotion and business development services. It provides systematic solutions based on customers' real needs, making brand information easily understandable to the public through "translation-simplification-scenario-based" methods. Meanwhile, with a reach of over 1 million vertical users across traffic channels, it achieves cooperation goals and helps partners complete a closed-loop marketing service from branding to business development. We have successfully organized dozens of offline biopharmaceutical R&D conferences with 1,000 attendees, covering fields such as small-molecule new drugs, large-molecule new drugs, improved new drugs, and cross-border BD transactions, serving more than a hundred listed/unicorn/biotech/pharmaceutical companies.